European Autism GEnomics Registry (EAGER):

Protocol for a multicentre cohort study and registry

4 Authors:

1

2

3

- 5 Bloomfield, M.^{1*}, Lautarescu, A.^{1*}, Heraty, S.², Douglas, S.³, Violland, P.³, Plas, R.³, Ghosh,
- 6 A.³, Van den Bosch, K.³, Eaton, E.⁴, Absoud, M.^{5,6}, Battini, R.^{7,8}, Blázquez Hinojosa, A.⁹,
- 7 Bolshakova, N. 10, Bolte, S. 11,12,13, Bonanni, P. 14, Borg, J. 15,16, Calderoni, S. 7,8, Calvo
- 8 Escalona, R. 9,17,18,19, Castelo-Branco, M. 20, Castro-Fornieles, J. 9,17,18,19, Caro P. 21, Danieli,
- 9 A.¹⁴, Delorme, R.²², Elia, M.²³, Hempel, M.²¹, Madeira, N.^{24,25,26}, McAlonan, G.^{27,28}, Milone,
- 10 R.⁷, Molloy, C. J.¹⁰, Mouga, S.^{29,30}, Montiel, V.³¹, Pina Rodrigues, A.^{29,30}, Schaaf, C. P.²¹,
- 11 Serrano, M.³¹, Tammimies, K.^{11,32}, Tye, C.¹, Vigevano, F.³³, Oliveira, G.^{34,35}, Mazzone, B.⁷,
- O'Neill, C.³⁶, Romero, V.³⁷, Tillmann, J.³⁸, Oakley, B.²⁷, Murphy, D.^{27,39,40}, Gallagher,
- 13 L. 10,41,42,43, Bourgeron, T. 44, Chatham, C. 45, Charman, T. 1
- * Indicates equal contribution

16 Affiliations:

- 17 1 Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's
- 18 College London, London, United Kingdom
- 19 2 Department of Psychological Sciences, University of London, Birkbeck, London, United
- 20 Kingdom
- 21 3 AIMS-2-Trials A-Reps, University of Cambridge, Cambridge, United Kingdom
- 4 Autism Research Centre, University of Cambridge, Cambridge, United Kingdom

- 23 5 Department of Children's Neurosciences, Evelina London Children's Hospital, Guy's and
- 24 St Thomas' NHS Foundation Trust, London, United Kingdom
- 25 6 Department of Women and Children's Health, Faculty of Life Sciences and Medicine,
- 26 School of Life Course Sciences, King's College London, London, United Kingdom
- 27 7 Department of Developmental Neuroscience, IRCCS, Fondazione Stella Maris, Pisa, Italy
- 28 8 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- 29 9 Department of Child and Adolescent Psychiatry and Psychology, Institute of
- 30 Neurosciences, Hospital Clínic Universitari, Barcelona, Spain
- 31 10 Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland
- 32 11 Center of Neurodevelopmental Disorders (KIND), Department of Women's and
- 33 Children's Health, Centre for Psychiatry Research, Karolinska Institutet & Region Stockholm,
- 34 Stockholm, Sweden
- 35 12 Child and Adolescent Psychiatry, Stockholm Health Care Services, Region Stockholm,
- 36 Stockholm, Sweden
- 13 Curtin Autism Research Group, Curtin School of Allied Health, Curtin University, Perth,
- 38 Australia
- 39 14 Epilepsy Unit, Scientific Institute IRCCS E. Medea Conegliano, Treviso, Italy
- 40 15 Centre for Psychiatry Research and Centre for Cognitive and Computational
- 41 Neuropsychiatry (CCNP), Department of Clinical Neuroscience, Karolinska Institutet &
- 42 Stockholm Health Care Services, Region Stockholm, Sweden
- 43 16 Psykiatri Affektiva, Sahlgrenska University Hospital, Gothenburg, Sweden
- 17 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- 18 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain

- 46 19 Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona,
- 47 Spain
- 48 20 CIBIT, ICNAS, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- 49 21 Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
- 50 22 Child and Adolescent Psychiatry Department, Robert Debre Hospital, APHP, Université
- 51 Paris Cité, Paris, France
- 52 23 Unit of Neurology and Clinical Neurophysiopathology, Oasi Research Institute-IRCCS,
- 53 Troina, Italy
- 54 24 Psychiatry Department, Centro Hospitalar e Universitário de Coimbra, Coimbra,
- 55 Portugal
- 56 25 Coimbra Institute for Biomedical Imaging and Translational Research, University of
- 57 Coimbra, Coimbra, Portugal
- 58 26 Institute of Psychological Medicine, Faculty of Medicine, University of Coimbra,
- 59 Coimbra, Portugal
- 60 27 Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry,
- 61 Psychology & Neuroscience, King's College London, London, United Kingdom
- 62 28 Behavioural and Developmental Clinical Academic Group, South London and Maudsley
- 63 NHS Foundation Trust, London, United Kingdom
- 64 29 CIBIT Coimbra Institute for Biomedical Imaging and Translational Research, University
- 65 of Coimbra, Coimbra, Portugal
- 66 30 ICNAS Institute of Nuclear Sciences Applied to Health, University of Coimbra,
- 67 Coimbra, Portugal
- 68 31 Pediatric Neurology Department, Hospital Sant Joan de Déu, Institut de Recerca Sant
- 69 Joan de Déu, Esplugues de Llobregat, Barcelona, Spain

- 70 32 Astrid Lindgren Children's Hospital, Karolinska University Hospital, Region Stockholm,
- 71 Stockholm, Sweden
- 72 33 Neurological Sciences and Rehabilitation Medicine Scientific Area Bambino Gesù
- 73 Children's Hospital, Rome, Italy
- 74 34 University Clinic of Pediatrics, Faculty of Medicine, University of Coimbra, 3000-602
- 75 Coimbra, Portugal
- 76 35 Child Developmental Center and Research and Clinical Training Center, Pediatric
- 77 Hospital, Centro Hospitalar e Universitário de Coimbra (CHUC), 3000-602 Coimbra, Portugal
- 78 36 Cure Sanfilippo Foundation
- 79 37 Dup15q Alliance
- 38 Roche Pharma Research and Early Development, Roche Innovation Center Basel,
- 81 Basel, Switzerland

- 82 39 South London and Maudsley NHS Foundation Trust (SLaM), London SE5 8AZ, UK
- 83 40 Institute for Translational Neurodevelopment, Institute of Psychiatry, Psychology &
- Neuroscience, King's College London, London WC2R 2LS, UK
- 41 Department of Psychiatry at The Hospital for Sick Children
- 86 42 Child and Youth Division Centre for Addiction and Mental Health, CAMH
- 43 Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto
- 88 44 Génétique Humaine et Fonctions Cognitives, Institut Pasteur, UMR3571 CNRS,
- 89 Université de Paris Cité, IUF, Paris, France
- 90 45 F. Hoffman-La Roche Ltd, Basel, Switzerland

Corresponding author Dr Alexandra Lautarescu, Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, Alexandra.Lautarescu@kcl.ac.uk

ABSTRACT

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

Introduction: Autism is a common neurodevelopmental condition with a complex genetic aetiology that includes contributions from monogenic and polygenic factors. Many autistic people have unmet healthcare needs that could be served by genomics-informed research and clinical trials. The primary aim of the European Autism GEnomics Registry (EAGER) is to establish a registry of participants with a diagnosis of autism or an associated rare genetic condition who have undergone whole-genome sequencing. The registry can facilitate recruitment for future clinical trials and research studies, based on genetic, clinical, and phenotypic profiles, as well as participant preferences. The secondary aim of EAGER is to investigate the association between mental and physical health characteristics and participants' genetic profiles. Methods and analysis: EAGER is a European multisite cohort study and registry and is part of the AIMS-2-TRIALS consortium. EAGER was developed with input from the AIMS-2-TRIALS Autism Representatives and representatives from the rare genetic conditions community. 1,500 participants with a diagnosis of autism or an associated rare genetic condition will be recruited at 13 sites across 8 countries. Participants will give a blood or saliva sample for whole-genome sequencing and answer a series of online questionnaires. Participants may also consent for the study to access pre-existing clinical data. Participants will be added to the EAGER registry. Data will be shared via the Autism Sharing Initiative, a new international collaboration aiming to create a federated system for autism data sharing. Ethics and dissemination: EAGER has received full ethical approval from ethics committees in the UK (REC 23/SC/0022), Germany (S-375/2023), Portugal (CE-085/2023) and Spain (HCB/2023/0038, PIC-164-22). Approvals are in the process of being obtained from committees in Italy, Sweden, Ireland, and France. Findings will be disseminated via scientific publications and conferences, but also beyond to participants and the wider community (e.g., the AIMS-2-TRIALS website, stakeholder meetings, newsletters).

STRENGHTS AND LIMITATIONS OF THIS STUDY Data from full genotyping through whole-genome sequencing will be combined with mental and physical health data and participant research priorities The EAGER sample (n=1,500), although relatively small for genetic analyses, will include a substantial proportion (around one third) of participants with a rare genetic condition, ensuring that heterogeneous presentations across the autism spectrum are captured The EAGER registry will improve the speed, efficiency, and impact of research studies and clinical trials across Europe with a culturally diverse cohort of re-contactable participants, and shared data through the Autism Sharing Initiative EAGER was developed with input from the AIMS-2-TRIALS Autism Representatives and representatives from the rare genetic conditions community Phenotypic data are collected only via self/informant-report questionnaires and not direct clinical assessments

1. INTRODUCTION

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

Autism is a neurodevelopmental condition diagnosed on the basis of differences in social communication and interaction, sensory processing, restricted and repetitive behaviours, and intense interests (1,2), with a prevalence of around 1-2% of the general population (3). Autism is associated with a very large number of common genetic variants of small effect (4), as well as being associated with several rare genetic conditions such as Dup15q syndrome, Rett syndrome, tuberous sclerosis complex, and Angelman syndrome, where autism prevalence is as high as 30-93% (5,6). Many autistic people have co-occurring mental and physical health conditions that impact quality of life, such as depression, anxiety, gastrointestinal symptoms, and epilepsy (7–12). For some autistic people and those with associated rare genetic conditions, many of these conditions can be severe and life-limiting, including respiratory and cardiac disorders in Rett syndrome (13,14), hyperphagia in Prader-Willi syndrome (15), and tumour growth in tuberous sclerosis complex (16). This makes the development of treatments and support for these populations a crucial area of research. Further, some autistic people may find aspects of being autistic distressing and disabling and may want help with these (17-20). All autistic people have the right to evidence-based care and support for aspects that are detrimental to their quality of life and wellbeing (21). Despite this, there is currently a paucity of personalised evidence-based care and support for autistic people across the spectrum (22,23), and polypharmacy (i.e., taking multiple medications) for various co-occurring symptoms is commonplace (24).

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

With a heritability of around 80%, autism has strong genetic influences (e.g., 25,26). However, to date, there is no known gene that, when mutated, increases the likelihood of an autism diagnosis without also increasing the likelihood of intellectual disability or other neurodevelopmental conditions (27). Consequently, genetic research is an important biomedical tool in the study of autism and associated rare genetic conditions, with benefits including personalised medicine, early identification of health risks, a better selfunderstanding, and a sense of community (28). To aid the development of evidence-based care for autistic people and those with associated rare genetic conditions, it is crucial to better understand genetic differences between syndromic forms of autism and autism without a known highly penetrant genetic influence. Further, by linking genetic mechanisms to treatment outcomes, autistic people and those with associated rare genetic conditions can be offered accurate information about what difficulties they may face both presently and in the future, and what interventions may be effective for aspects of their lived experience that they want or need support with. EAGER (European Autism GEnomics Registry) is a European multicentre study that aims to create a registry of 1,500 participants with a diagnosis of autism or a rare genetic condition associated with autism. Participants will give a biosample and whole-genome sequencing will be performed on extracted DNA; participants will also answer a series of questionnaires related to autism, quality of life, mental and physical health, and research preferences. Using extensive genetic and phenotypic data, EAGER will enable a better understanding of the genetic architecture of autism and associated rare genetic conditions, as well as the relationship between genetics and outcomes such as health, quality of life, and wellbeing. The EAGER registry will allow participants to be recontacted for future research studies or clinical trials that may be suitable for them. This will facilitate research by streamlining and


accelerating recruitment across Europe, as well as bring together key research and clinical institutions, to the benefit of participants and their families. In line with tailoring evidencebased care to specific populations, clinical trials that are genetically-informed allow researchers to invite participants who are the most suited to, and may benefit most from, a treatment (29). Selective recruitment at the early stages of treatment development encourages the downstream development of personalised medicine. This project aims to be a catalyst for future research and clinical trials in autism and associated rare genetic conditions in Europe. This will be achieved by connecting key sites and allowing research groups and pharmaceutical companies planning research studies or clinical trials to have access to a European registry of people who have consented to being recontacted. EAGER data will also be shared via the Autism Sharing Initiative (ASI), a global collaboration connecting autism data through federated mechanisms (30). The genetic, phenotypic, and clinical data collected in EAGER can therefore be analysed with other international autism datasets such as MSSNG (31), POND (32), LEAP (33), SPARK (34), and Searchlight (35), providing the opportunity to investigate key research questions.

2. METHODS AND ANALYSIS

2.1. Study design and population

EAGER is an international, multisite registry of adults and children with a diagnosis of autism or associated rare genetic conditions. Recruitment for EAGER will take place at 13 sites across 8 European countries (see figure 1).

Figure 1. EAGER collaborating centres




To be eligible, participants need to be over 2 years of age and have a diagnosed rare genetic condition associated with autism and/or have a diagnosis of autism (see figure 2).

Decisions regarding which conditions and genetic variants to include have been made on the

basis of published literature (36) and discussions with experts in the field (TB, LG), with consideration given to the penetrance, prevalence, and association with autism. For participants with a diagnosis of autism only, and where existing genetic information is available, recruitment will prioritise individuals within multiplex families and individuals with genetic variants associated with autism (see figure 2). Participants will not be excluded from the study based on any other characteristics such as co-occurring conditions, sex, or intellectual disability.

Figure 2. EAGER protocol summary



2.2. Patient and public involvement and ethical consultations

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

Genetic research can involve complex ethical challenges, making it crucial to prioritise ethical considerations and participatory research practices (21,28). Participatory research practices can help ensure that the interests of our participants are appropriately represented and that the study is beneficial to its participants and the wider community. EAGER was developed with crucial input and feedback from community representatives via dedicated working groups. Our autism working group consists of AIMS-2-TRIALS Autism Representatives: autistic people and family members or carers of autistic people. Our rare genetic conditions working group consists of parents/carers of people with rare genetic conditions and/or representatives from European rare genetic conditions associations. As EAGER was conceptualised and funded prior to the establishment of our lived experience working groups, it is not a fully participatory research endeavour. This was discussed with and understood by all members of the working groups at the outset of our collaboration. Within these constraints, every effort was made to consult with our lived experience partners throughout the lifespan of this project, and feedback was integrated to the greatest degree possible. The EAGER working groups have offered invaluable advice and feedback to guide the planning process of EAGER (see Box 1), either as part of working group meetings or through communication via email or contributions to collaborative documents. Open discussion within these groups was encouraged; as the groups included a variety of perspectives, there were naturally different solutions to questions. When no consensus was reached, the core research team made the final decision based on feasibility.

301 Box 1. Key examples of how patient and public involvement guided the EAGER study

- Refining the study rationale and clarifying perceived benefit of the study for autistic people
- Deciding on study name and logo
- Discussing ethical implications of the research, ensuring that appropriate safeguards are in place and that any limitations are transparently communicated to participants
- Ensuring that the information presented in study documents is clear, accessible, transparent,
 and sufficient to allow participants to make an informed decision about their participation
- Creating a "Data sharing Frequently Asked Questions" document to accompany the information sheet
- Developing different versions of information sheets tailored to the needs of our different participant groups (e.g., easy-read, adolescent information sheet)
- Ensuring that the consent forms are clear and transparent about what precisely a participant is consenting to
- Ensuring that the language used in study documents is appropriate and in line with community preferences
- Discussing the phenotypic measures used in the study and suggesting changes to the content/language of questionnaires
- Sharing all key study documents for feedback prior to submission for ethical approval
- Clearly stating that EAGER is against eugenics / prenatal testing for autism on participantfacing documents
- Detailing exactly what analyses will be performed on participant data and making it clear that no further analyses will occur without reconsenting
- Clarifying that analyses performed on EAGER data will need to be approved by a committee before they can begin
- Clarifying in the ethics documents that not all decisions were made based on consensus
- Adding a disclaimer in the protocol/ethics with regards to the fact that citing papers does not represent an endorsement of the language/aims of those papers or of the authors

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

Further, we conducted consultation with other stakeholders, ethical advisors, and additional working groups within the consortium, in order to evaluate risks and potentially sensitive implications of this research. We hope that the aforementioned groups will guide EAGER in the most beneficial direction for its participants and the wider community. These groups will continue to be consulted throughout the lifetime of the project. 2.3. Participant recruitment, information sheets, and informed consent Potential participants will be approached by representatives at each local site. Each site will screen and recruit participants based upon recontact of participants from prior research studies or prior/current patients that fit the inclusion criteria. Written informed consent will be required for participation in the study and participants will be provided with information sheets tailored to their age and levels of intellectual disability (see figure 2 for details on documents for specific participant groups). A personal consultee will be asked to consent on behalf of individuals who are deemed to not have capacity to consent following a capacity to consent assessment. Due to the high prevalence of cooccurring intellectual disability in people with rare genetic conditions, these may make up a significant proportion of the overall sample. Parental consent will be required for those under the legal age of consent (e.g., 16 years old in the UK). To take part in EAGER, participants must consent to core aspects of the study: giving a blood or saliva sample (or permission to use a pre-existing sample), completing questionnaires, being added to the registry, and data sharing.

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

2.4. Biological sample collection Participants will give a blood or saliva sample, depending on preference and appropriateness. The Oragene® DNA self-collection kits, as well as assisted collection kits for those unable to collect their own sample, will be used for saliva collection. If existing blood or saliva samples are available and have been stored appropriately, they can be used in lieu of a new sample, with participant consent. 2.5. Measures Following collection of the biological sample, participants will be given access to an online form with a series of questionnaires, focussing on autism, rare genetic conditions, cooccurring physical and mental health conditions, opinions on research priorities, and quality of life and wellbeing (see table 1). These will be a mixture of validated and non-validated questionnaires that have been adapted for EAGER, and have been chosen to overlap with other major initiatives or studies both within AIMS-2-TRIALS (37,38) and externally, such as MSSNG (31), POND (32), LEAP (33), SPARK (34), and Simon's Searchlight (35). All questionnaires have been translated into the local language of each site from English. The online questionnaires will be completed by participants answering on behalf of themselves, or by parents and consultees answering on behalf of the participant.

Table 1. EAGER questionnaires

Domain	Measure	Description	Respondents
Autism traits	Social Responsiveness Scale (SRS (39))	65 items: Autism traits (including social awareness, cognition, communication, motivation, and repetitive interests and behaviours)	Adult self-report
	Social Communication Questionnaire (SCQ, (40))	40 items: Autism traits (including communication skills and social functioning)	Parent or consultee report for child or adult
Mental health	Strengths and Difficulties Questionnaire (SDQ, (41))	25 items: General mental health across five scales (conduct problems, hyperactivity, emotional problems, peer problems, prosocial behaviour)	Parent or consultee report for adult or child
	Patient Health Questionnaire-9 (PHQ-9, (42))	9 items: Core features of major depressive disorder	Adult self-report
	Patient Health Questionnaire-A (PHQ-A, (43)) Generalised Anxiety Disorder-	9 items: Core features of major depressive disorder* 7 items: Core features of generalised	Adolescent (16 and 17 years) self-report Adult self-report
	7 (GAD-7, (44))	anxiety disorder	
Quality of life	World Health Organization Quality of Life-BREF (WHO- QOL-BREF, (45))	26 items: Quality of life across four domains (physical health, psychological health, social relationships, environment)	Adult self-report
	Cantrill Ladder (46)	1 item: Subjective quality of life (10 point scale from "worst possible life" to "best possible life")	Adult self-report. Parent or consultee report for child or adult.
Mental wellbeing	Warwick-Edinburgh Mental Wellbeing Scales (WEMWBS,	14 items: Mental wellbeing and health	Adult self-report. Parent or consultee

	(47))		self-report +
Restrictive and repetitive	Adult Routines inventory (ARI, (48))	55 items: Restrictive and repetitive behaviours	Adult self-report
behaviours	Repetitive Behaviours Scale- Revised (RBS-R, (49))	43: Assessing restrictive and repetitive behaviours	Parent or consultee report for child or adult
ADHD	Conners' Adult ADHD Rating Scales (CAARS, (50))	26 items: Core features of ADHD	Adult self-report
	ADHD Rating Scale (51))	18 items: Core features of ADHD	Parent report for child Consultee report for adult^
Demographics	Non-validated questionnaire	16-25 items: Demographic characteristics	Adult self-report. Parent or consultee report for child or adult.
Co-occurring conditions	Non-validated questionnaire (adapted from Simons Searchlight (35))	Items assessing 168 diagnosed and self-diagnosed psychiatric, neurodevelopmental, and physical health conditions.	Adult self-report. Parent or consultee report for child or adult.
Medications	Non-validated questionnaire	1 item: Number of medications taken by participant per day	Adult self-report. Parent or consultee report for child or adult.
General functioning	Non-validated questionnaire (adapted from (52))	7-11 items: Seizures, gross motor skills, language and communication,	Adult self-report. Parent or consultee
		intellectual disability, support needs, sleep	report for child or adult.
Voice of the community	Non-validated questionnaire (adapted from Simon	7-13 items: Priorities for research	Adult self-report. Parent or consultee

		Searchlight (35))		report for child or		
				adult.		
353	* Additional questions and assessment of suicidality in the original measure were removed for the purpose of this study and					
354	only the first core	9 items were included.				
355	^ The ADHD rating scale was adapted for use in EAGER to make it appropriate for adults and remove child-specific language.					
356	⁺ Administered to parents and caregivers in relation to their own mental wellbeing.					
357						
358						
359	2.6. D	ata analysis				
360	EAGER will o	collect genetic and phenoty	pic data, which can be analysed b	ooth alone and in		
361	conjunction with other data collected within AIMS-2-TRIALS and/or shared via the ASI.					
362	Research questions will be decided in collaboration with our community working groups.					
363	Examples include identifying genetic variants that are associated with aspects of the core					
364	autism phenotype or conditions such as epilepsy or major depressive disorder, and					
365	identifying the association between genetic variants and/or polygenic scores and traits such					
366	as quality of life, levels of cognitive ability and executive function. The sample size of this					
367	study (n=1,500), which was driven by the available budget, is moderate-to-large in the field					
368	and will be significantly enhanced via the planned data sharing and integration.					
369						
370						
371						
372						
373						
374						
375						

3. DATA SHARING AND EAGER REGISTRY

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

3.1. Data sharing Currently, funding bodies and participant groups have identified the need for research groups to share their data to maximise the value of each research contribution, pool data to address research questions that require a larger number of participants, or to carry out metaanalyses (53). For this reason, EAGER data will be shared via established AIMS-2-TRIALS data sharing mechanisms as well as being directly implemented into the ASI as detailed below. Rigorous safeguards will be implemented for access to data via established AIMS-2-TRIALS mechanisms and via the ASI platform (30). Researchers will not be able to access EAGER data without approval from a data access committee, which will consist of autistic and non-autistic people, researchers, and members of the rare genetic community. 3.1.1. Autism Sharing Initiative (ASI) The ASI is a new collaboration working to create the first federated, global network for sharing genomic and clinical data in autism research. The ASI is led by software company DNAStack and involves other collaborators such as Autism Speaks, Roche, and the Ontario Brain Institute (please see (54) for the full list). This is an ongoing project and new collaborators may be added. Data sharing within the ASI will be built upon decentralised, federated data sharing principles. Data federation allows researchers to search, access, and analyse data that reside in different locations and are connected via a network, without the need for data to be moved between institutions/researchers.

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

Data federation allows researchers to interrogate and analyse data hosted in different locations, in compliance with data regulations and improving privacy and security. A federated data network involves connecting individual datasets, which remain in their protected local environments (i.e., at the research institution where the data was collected), across one cloud-based network. To our knowledge, the ASI carries no additional risk to participant re-identification than traditional data sharing. The ASI software is built upon security standards developed by the Global Alliance for Genomics and Health (55), and regularly updated in order to ensure that data are safeguarded. Within the ASI, data will include genomic, multi-omic, medical, and clinical data from international autism research sources. With participant consent, EAGER data (genetic data, data from online questionnaires, and existing data held at local sites) will be shared through the ASI platform with any explicit identifiers removed. 3.2. EAGER registry The EAGER registry will allow participants to be contacted for future clinical trials and research studies. Researchers viewing shared participant data will be able to contact the coordinating site (King's College London) to request specific participant groups based upon their desired criteria without access to participant personal information. King's College London will pass these requests onto the relevant local sites, who can send information about the study or clinical trial to participants. 4. ETHICS AND DISSEMINATION

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

Ethics 4.1. EAGER has received full ethical approval from ethics committees in the UK (REC 23/SC/0022), Germany (S-375/2023), Portugal (CE-085/2023) and Spain (HCB/2023/0038, PIC-164-22). Approvals are in the process of being obtained from ethics committees in Italy, Sweden, Ireland, and France. Please refer to the above section "Patient and Public Involvement and Ethics Consultation" for detail on ethics and discussions within our community working groups. 4.2. Dissemination We plan to disseminate our findings widely via academic avenues, such as publications in peer-reviewed major international scientific journals and conferences. In addition, we will disseminate beyond academic avenues to ensure that our findings reach participants and the wider communities, including the AIMS-2-TRIALS website (www.aims2trials.eu), stakeholder meetings, and newsletters. As part of the overall AIMS-2-TRIALS project, we have access to a European network including researchers, clinicians, and families within the autism community. This network will also provide a forum for dissemination of research findings and training opportunities. Disclaimer: Citing papers does not represent an endorsement of the language used in these papers, nor of the aims of the research or researchers. **REFERENCES**

- 1. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum
- 451 disorder. Nat Rev Dis Primers. 2020 Jan 16;6(1):1–23.
- 452 2. Kodak T, Bergmann S. Autism Spectrum Disorder: Characteristics, Associated
- 453 Behaviors, and Early Intervention. Pediatr Clin North Am. 2020 Jun;67(3):525–35.
- 454 3. Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. Global
- prevalence of autism: A systematic review update. Autism Res. 2022 May:15(5):778–90.
- 456 4. Willsey HR, Willsey AJ, Wang B, State MW. Genomics, convergent neuroscience and
- progress in understanding autism spectrum disorder. Nat Rev Neurosci. 2022
- 458 Jun;23(6):323-41.
- 5. Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum
- disorder phenomenology in genetic disorders: a systematic review and meta-analysis.
- 461 The Lancet Psychiatry. 2015 Oct 1;2(10):909–16.
- 462 6. Lusk L, Vogel-Farley V, DiStefano C, Jeste S. Maternal 15q Duplication Syndrome. In:
- Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors.
- 464 GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited
- 465 2022 May 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK367946/
- 466 7. Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-
- occurring mental health diagnoses in the autism population: a systematic review and
- meta-analysis. Lancet Psychiatry. 2019 Oct;6(10):819–29.
- 469 8. Tye C, Runicles AK, Whitehouse AJO, Alvares GA. Characterizing the Interplay
- 470 Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative
- 471 Review. Front Psychiatry. 2018;9:751.

- 472 9. van Heijst BF, Deserno MK, Rhebergen D, Geurts HM. Autism and depression are
- 473 connected: A report of two complimentary network studies. Autism. 2020 Apr;24(3):680–
- 474 92.
- 475 10. Hollocks MJ, Lerh JW, Magiati I, Meiser-Stedman R, Brugha TS. Anxiety and depression
- in adults with autism spectrum disorder: a systematic review and meta-analysis.
- 477 Psychological Medicine. 2019 Mar;49(4):559–72.
- 478 11. Wang J, Ma B, Wang J, Zhang Z, Chen O. Global prevalence of autism spectrum
- disorder and its gastrointestinal symptoms: A systematic review and meta-analysis.
- 480 Front Psychiatry. 2022 Aug 23;13:963102.
- 481 12. Besag FM. Epilepsy in patients with autism: links, risks and treatment challenges.
- 482 Neuropsychiatr Dis Treat. 2017 Dec 18;14:1–10.
- 483 13. Acampa M, Guideri F. Cardiac disease and Rett syndrome. Arch Dis Child. 2006
- 484 May;91(5):440-3.
- 14. Katz DM, Dutschmann M, Ramirez JM, Hilaire G. Breathing Disorders in Rett Syndrome:
- 486 Progressive Neurochemical Dysfunction in the Respiratory Network after Birth. Respir
- 487 Physiol Neurobiol. 2009 Aug 31;168(1–2):101–8.
- 488 15. Driscoll DJ, Miller JL, Cassidy SB. Prader-Willi Syndrome. In: Adam MP, Mirzaa GM,
- 489 Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors. GeneReviews® [Internet].
- Seattle (WA): University of Washington, Seattle; 1993 [cited 2023 Sep 18]. Available
- 491 from: http://www.ncbi.nlm.nih.gov/books/NBK1330/
- 492 16. Islam MP. Tuberous Sclerosis Complex. Semin Pediatr Neurol. 2021 Apr;37:100875.
- 17. Schaaf RC, Toth-Cohen S, Johnson SL, Outten G, Benevides TW. The everyday
- routines of families of children with autism: examining the impact of sensory processing
- difficulties on the family. Autism. 2011 May;15(3):373–89.

- 496 18. Green D, Chandler S, Charman T, Simonoff E, Baird G. Brief Report: DSM-5 Sensory
- 497 Behaviours in Children With and Without an Autism Spectrum Disorder. J Autism Dev
- 498 Disord. 2016 Nov 1;46(11):3597–606.
- 499 19. Lai MC, Anagnostou E, Wiznitzer M, Allison C, Baron-Cohen S. Evidence-based support
- for autistic people across the lifespan: maximising potential, minimising barriers, and
- optimising the person-environment fit. Lancet Neurol. 2020 May;19(5):434–51.
- 502 20. Lord C, Charman T, Havdahl A, Carbone P, Anagnostou E, Boyd B, et al. The Lancet
- 503 Commission on the future of care and clinical research in autism. The Lancet. 2022
- 504 Jan;399(10321):271-334.
- 505 21. Heraty S, Lautarescu A, Belton D, Boyle A, Cirrincione P, Doherty M, et al. Bridge-
- building between communities: Imagining the future of biomedical autism research. Cell.
- 507 2023 Aug 31;186(18):3747–52.
- 508 22. Sandbank M, Bottema-Beutel K, Crowley S, Cassidy M, Dunham K, Feldman JI, et al.
- Project AIM: Autism intervention meta-analysis for studies of young children.
- 510 Psychological Bulletin. 2020;146(1):1–29.
- 23. Braga LAM, Conte Filho CG, Mota FB. Future of genetic therapies for rare genetic
- diseases: what to expect for the next 15 years? Ther Adv Rare Dis. 2022 Jun
- 513 10;3:26330040221100840.
- 514 24. Feroe AG, Uppal N, Gutiérrez-Sacristán A, Mousavi S, Greenspun P, Surati R, et al.
- 515 Medication Use in the Management of Comorbidities Among Individuals With Autism
- Spectrum Disorder From a Large Nationwide Insurance Database. JAMA Pediatrics.
- 517 2021 Sep 1;175(9):957–65.

518 25. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of 519 Genetic and Environmental Factors With Autism in a 5-Country Cohort. JAMA 520 Psychiatry. 2019 Oct 1;76(10):1035-43. 521 26. Tick B, Bolton P, Happé F, Rutter M, Rijsdijk F. Heritability of autism spectrum disorders: 522 a meta-analysis of twin studies. Journal of Child Psychology and Psychiatry. 523 2016;57(5):585-95. 524 27. Myers SM, Challman TD, Bernier R, Bourgeron T, Chung WK, Constantino JN, et al. 525 Insufficient Evidence for "Autism-Specific" Genes. Am J Hum Genet. 2020 May 526 7:106(5):587-95. 527 28. Natri HM, Chapman CR, Heraty S, Dwyer P, Walker N, Kapp SK, et al. Ethical 528 challenges in autism genomics: Recommendations for researchers. European Journal of 529 Medical Genetics. 2023 Sep 1;66(9):104810. 530 29. Díaz-Caneja CM, State MW, Hagerman RJ, Jacquemont S, Marín O, Bagni C, et al. A 531 white paper on a neurodevelopmental framework for drug discovery in autism and other 532 neurodevelopmental disorders. Eur Neuropsychopharmacol. 2021 Jul;48:49-88. 533 30. DNAstack [Internet]. [cited 2023 Oct 8]. DNAstack launches Neuroscience AI to 534 accelerate collaborative research and discovery, DNAstack. Available from: 535 https://dnastack.com/news-neuroscience-ai-launch-announcement/ 536 31. MSSNG [Internet]. [cited 2023 Sep 18]. Available from: https://research.mss.ng/ 537 32. POND. Your Research Priorities [Internet]. Province of Ontario Neurodevelopmental 538 Network. [cited 2023 Apr 11]. Available from: https://pond-network.ca/your-research-539 priorities/

- 540 33. Charman T, Loth E, Tillmann J, Crawley D, Wooldridge C, Goyard D, et al. The EU-
- AIMS Longitudinal European Autism Project (LEAP): clinical characterisation. Molecular
- 542 Autism. 2017 Jun 23;8(1):27.
- 34. SPARK [Internet]. [cited 2023 Sep 18]. Available from: https://sparkforautism.org/
- 35. SFARI [Internet]. 2019 [cited 2023 Sep 18]. SFARI | Simons Searchlight. Available from:
- 545 https://www.sfari.org/resource/simons-searchlight/
- 36. Rolland T, Cliquet F, Anney RJL, Moreau C, Traut N, Mathieu A, et al. Phenotypic
- effects of genetic variants associated with autism. Nat Med. 2023 Jul;29(7):1671–80.
- 548 37. AIMS-2-TRIALS Autism Research For Europe [Internet]. 2018 [cited 2023 Oct 8].
- 549 Available from: https://www.aims-2-trials.eu/
- 38. Oakley BFM, Loth E, Jones EJH, Chatham CH, Murphy DG. Advances in the
- identification and validation of autism biomarkers. Nat Rev Drug Discov. 2022
- 552 Oct;21(10):697-8.
- 39. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al.
- Validation of a Brief Quantitative Measure of Autistic Traits: Comparison of the Social
- 555 Responsiveness Scale with the Autism Diagnostic Interview-Revised. J Autism Dev
- 556 Disord. 2003 Aug 1;33(4):427–33.
- 557 40. (SCQ) Social Communication Questionnaire [Internet]. [cited 2023 Sep 18]. Available
- from: https://www.wpspublish.com/scq-social-communication-questionnaire.html
- 41. Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child
- 560 Psychol Psychiatry. 1997 Jul;38(5):581–6.
- 42. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
- measure. J Gen Intern Med. 2001 Sep;16(9):606–13.

- 43. Johnson JG, Harris ES, Spitzer RL, Williams JBW. The patient health questionnaire for
- adolescents: validation of an instrument for the assessment of mental disorders among
- adolescent primary care patients. J Adolesc Health. 2002 Mar;30(3):196–204.
- 44. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing
- Generalized Anxiety Disorder: The GAD-7. Archives of Internal Medicine. 2006 May
- 568 22;166(10):1092–7.
- 569 45. WHOQOL Measuring Quality of Life | The World Health Organization [Internet]. [cited
- 570 2023 Sep 18]. Available from: https://www.who.int/tools/whogol
- 571 46. Cantril H. The pattern of human concerns. New Brunswick, N.J.: Rutgers University
- 572 Press; 1966. 427 p.
- 47. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-
- 574 Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health
- and Quality of Life Outcomes. 2007 Nov 27;5(1):63.
- 48. Evans DW, Uljarević M, Lusk LG, Loth E, Frazier T. Development of Two Dimensional
- 577 Measures of Restricted and Repetitive Behavior in Parents and Children. Journal of the
- 578 American Academy of Child & Adolescent Psychiatry. 2017 Jan 1;56(1):51–8.
- 579 49. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Repetitive Behavior Scale-Revised
- [Internet]. 2014 [cited 2023 Sep 18]. Available from:
- 581 http://doi.apa.org/getdoi.cfm?doi=10.1037/t17338-000
- 582 50. Macey KD. Conners' Adult ADHD Rating Scales (CAARS). Archives of Clinical
- 583 Neuropsychology. 2003 May 1;18(4):431–7.
- 51. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale—IV: Checklists,
- 585 norms, and clinical interpretation. New York, NY, US: The Guilford Press; 1998. viii, 79
- p. (ADHD Rating Scale—IV: Checklists, norms, and clinical interpretation).

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

52. Keute M, Miller MT, Krishnan ML, Sadhwani A, Chamberlain S, Thibert RL, et al. Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment. Mol Psychiatry. 2021 Jul;26(7):3625-33. 53. Lombardo MV, Lai MC, Baron-Cohen S. Big data approaches to decomposing heterogeneity across the autism spectrum. Mol Psychiatry. 2019 Oct;24(10):1435-50. 54. Digital Supercluster [Internet]. [cited 2023 Oct 8]. Autism Sharing Initiative. Available from: https://www.digitalsupercluster.ca/projects/autism-sharing-initiative/ 55. Global Alliance for Genomics and Health. Enabling responsible genomic data sharing for the benefit of human health [Internet]. 2023 [cited 2023 Apr 11]. Available from: https://www.ga4gh.org/ **AUTHOR CONTRIBUTIONS:** Conceptualisation: MB, AL, SH, SD, PV, RP, AG, KVdB, EE, CO, VR, JT, BO, DM, LG, TB, CC, TC. Funding acquisition: DM, CC, TC. Project administration: MB, AL, DM, LG, TB, CC. TC. Supervision: AL, TC. Visualisation: MB, AL. Data collection: MB, AL, MA, RB, ABH, NB, SB, PB, JB, SC, RCE, MCB, JCF, PC, AD, RD, ME, MH, NM, GM, RM, CJM, SM, VM, APR, CPS, MS, KT, CT, FV, GO, BM, LG, TC. Writing - original draft: MB, AL, TC. Writing - review and editing: All authors **FUNDING STATEMENT:** This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394 for the project AIMS-2-TRIALS. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation

programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI and from Horizon Europe [grant agreement no. 101057385] and from Horizon Europe [grant agreement no. 101057385] and from UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee [grant no.10039383] (R2D2-MH). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Any views expressed are those of the author(s) and not necessarily those of the funders. In addition, SB receives funding from Swedish Research Council and Region Stockholm. CT receives funding from Epilepsy Research UK, Autistica, the Baily Thomas Charitable Fund and the Tuberous Sclerosis Association. LG receives funding from Horizon Europe: Risk and Resilience in Developmental Diversity and Mental Health (R2D2-MH). CPS receives funding from Foundation of Prader-Willi Research, European Joint Program for Rare Diseases, Illumina, German Children's Cancer Foundation, and the German Ministry of Education and Research. RB, RM, SC, BM receive funding from the Italian Ministry of Health (Ricerca Corrente and 5x1000 to IRCCS Fondazione Stella Maris). Genomic data utilised here will be sequenced in part/whole through the financial contribution of F Hoffmann La-Roche. This paper represents independent research part-funded by the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

COMPETING INTEREST STATEMENT:

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

In the past 3 years TC has served as a paid consultant to F. Hoffmann-La Roche Ltd. and Servier and has received royalties from Sage Publications and Guilford Publications. DM has received funding for a PhD studentship from Compass, and for consulting from Jaguar Therapeutics and Hoffman Le Roche. GM receives funding for an investigator-initiated study from Compass Pathways; no financial or other conflict of interest with the present study. SB

discloses that he has in the last 3 years acted as an author, consultant, or lecturer for Medice, Roche, and Linus Biotechnology. SB receives royalties for textbooks and diagnostic tools from Hogrefe, UTB, Ernst Reinhardt, Kohlhammer, and Liber, and is a partner at NeuroSupportSolutions International AB. CC is a full-time employee of Genentech and owns stocks or RSUs in Roche Holdings, Ltd. MA is the UK chief investigator for a trial sponsored by Roche (a phase II, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, efficacy, and pharmacodynamics of 52 weeks of treatment with basmasanil in participants aged 2 to 14 years old with dup15q syndrome followed by a 2-year optional open-label extension). LB served on an advisory board to Kingdom therapeutics in 2022.

WORD COUNT: 2418